By Kenton Morgan, DVM, DACT
Increasingly, some compounding pharmacies are offering (1) preparations that are very similar to approved products, (2) a new formulation of an approved ingredient (e.g. an injectable form of omeprazole), and (3) formulations of new products containing active ingredients not approved in the U.S. market (e.g. toltrazuril—and there are three FDA-approved products labeled for use in horses for treatment of EPM). Although these may be tempting to consider, equine practitioners should consider what constitutes the standard of care and our ethical obligation to provide that level of care to our patients.
Related Guidelines
Position on the Use of Medroxyprogesterone Acetate in Competition Horses
Medroxyprogesterone acetate (MPA) is a synthetic progestin hormone administered to mares off-label…
Position on the Use of Vesicants
The AAEP does not support the use of vesicants and internal blistering…
Position on the Use of Hog Rings
Cribbing (also known as crib biting or windsucking) is one of many…